Author:
Ajani Mustapha Akanji,Salami Ayodeji Akeem,Awolude Olutosin Alaba,Oluwasola Abideen Olayiwola
Abstract
Background: Triple negative epithelial ovarian cancer (TNEOC) refers to ovarian carcinomas that do not express estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor- type 2 (HER-2/neu). The aim of this study is to determine the pattern of triple negative epithelial ovarian cancer in indigenous African women. Methods: We performed a retrospective review of ER, PR and HER-2/neu expression in 90 Nigerian patients with histologically diagnosed epithelial ovarian cancer. Lack of expression of ER, PR and HER2/neu antigens was used to determine carcinomas that are among the TNEOC. We also compared the clinicopathological parameters (age, International Federation of Gynaecology and Obstetrics (FIGO) stage, grade and histological subtype) in patients with TNEOC and non- TNEOC . Results: Thirty-eight (42.2%) of the 90 tumours diagnosed as EOC were negative for ER, PR and HER2/neu expression. There was no significant association between TNEOC with other parameters such as age, FIGO stage and histological grade. Sixteen (66.7%) of the 24 mucinous carcinomas were triple negative, while only 21 (33.3%) of the 63 serous carcinomas were triple-negative and one (50%) of the two endometrioid carcinomas was triple negative. There was a significant association between triple-negative tumours and histological subtypes of EOC (p = 0.034). Conclusions: A subtype of epithelial ovarian cancer that is negative for ER, PR and HER-2/neu has been discovered in indigenous African women. TNEOC expression is high and is comparable to the triple negative breast cancer subtype seen in people of African ancestry. Future study of TNEOC in a large sample size should be considered.
Subject
General Pharmacology, Toxicology and Pharmaceutics,General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference27 articles.
1. Ovarian cancer: etiology, risk factors, and epidemiology.;J Hunn;Clin Obstet Gynaecol.,2012
2. Global cancer statistics.;A Jemal;CA Cancer J Clin.,2011
3. Targeted therapies in epithelial ovarian cancer.;N Barrena Medel;J Oncol.,2010
4. Clinicopathological analysis of ovarian tumors--a study on five years samples.;G Swamy;Nepal Med Coll J.,2010
5. New therapies for ovarian cancer: cytotoxics and molecularly targeted agents.;P Dinh;Crit Rev Oncol Hematol.,2008